| Project/Area Number |
25670650
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Ozaki Toshifumi 岡山大学, 医歯(薬)学総合研究科, 教授 (40294459)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIHARA SHINSUKE 独立行政法人国立病院機構, 四国がんセンター(臨床研究センター), 研究員 (60314671)
TAKEDA KEN 岡山大学, 医歯(薬)学総合研究科, 助教 (70614923)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 骨肉腫 / 薬剤耐性 / 質量分析 / 薬剤耐性株 / 骨軟部肉腫 / SILAC |
|---|
| Outline of Final Research Achievements |
Chemoresistance is a poor prognostic factor in osteosaroma and is a major obstacle to the successful treatment of patients receiving chemotherapy. However, the precise mechanism of resistance remains unclear. In this study, a pair of osteosarcoma cell lines, MNNG/HOS, U2OS and its adriamycin-resistant counterpart MNNG/HOS-ADR and U2OS/ADR were used to examine resistance-dependent cellular responses and to identify potential chemotherapeutic resistant targets. About three thousand proteins were identified in this study.
|
